

ANTEO ANNOUNCES RETIREMENT OF CEO

For Immediate Release:

March 16, 2016

Anteo Diagnostics Limited (**ASX: ADO**) (“**Anteo**” or the “**Company**”) wishes to announce that Chief Executive Officer, Dr Geoff Cumming has today advised his intention to retire and appoints Dr Jef Vangenechten as its Global Chief Executive Officer.

Dr Cumming commenced his tenure with Anteo in 2009, initially as CEO, before being appointed to the Board. He will assist the Board during the next six months as Anteo transitions to the new CEO and structure which will include the recruitment of a Chief Operating Officer and Financial Officer based in Brisbane to support the further commercialisation of Anteo’s platform technology.

The Board is in the fortunate position of having an internal successor available. Jef Vangenechten is currently the Chief Executive Officer of Diasource Immunoassays S.A., and he has agreed to step into a combined role as Global CEO. He is a veteran of the bio-technology industry in Europe, and holds a PhD in Biology and Physiology. He will be based in Brussels and travel regularly to Brisbane, Australia where the research and development will remain based. Jef will take up the role formally on 1 June 2016.

Of his resignation, Dr Cumming commented, “While I am sad to be moving on from Anteo, I am pleased to be transitioning at a time when the business is in a sound position. The DIAsource acquisition has successfully closed, the company is well funded and now work is in hand to further integrate the businesses and grow the core surface modification technology. It is an appropriate time for me to pass the reins over to a new CEO who can continue to build on Anteo’s foundations, which are now in a stronger position than they have ever been.

“My time at Anteo has been a pleasure and I wish to express my sincere thanks to the Board, our employees and shareholders for all the support over the years. I will continue to watch the business with interest during my retirement.”

Mr Mark Bouris, Chairman of Anteo commented, “Geoff has led Anteo since 2009. He was instrumental in bringing about the recent acquisition of Belgian-based diagnostics company, DIAsource Immunoassays SA, and raising the necessary funds. These achievements will be pivotal in seeing Anteo move toward a cash flow positive position.

“During Geoff’s tenure, Anteo’s core surface modification technology has achieved commercialisation in a number of areas of application under the ‘Mix&Go’ brand. He also led important advancements in the application of Anteo’s technologies in promising new areas, including medical devices and battery technology.

“On behalf of the Board, I wish to extend my thanks to Geoff for his significant contribution and wish him well in his retirement.”

For further information, contact Shane Hartwig, Company Secretary: Phone: +61 7 3219 0085

About Anteo Diagnostics Limited

Anteo Diagnostics Limited (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the life sciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets. The Anteo group owns a patented nanoglue technology, which is used by healthcare customers for incorporation into their existing tests and tests under development, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests. This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company's target markets, due to its ability to revolutionise the way scientists work. While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being conducted into the viability of this battery product. For more information, please visit www.anteodx.com